COMPARISON
Terlipressin vs Vasopressin
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Terlipressin is authorised or registered in 8 and Vasopressin in 7 of the 10 registers read. Terlipressin: highest phase Phase 3 (2 phase 3 trials, 0 with posted results). Vasopressin: highest phase Phase 4 (after approval). 88 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Terlipressin | Vasopressin | |
|---|---|---|
| Registered trials differs | 118 clinicaltrials.gov · 2026-10-03 | 449 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Terlivaz openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VASOPRESSIN openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Terlipressin | placebo | Vasopressin | placebo |
|---|---|---|---|---|
| Abdominal pain | 21.8% | 13.4% | - | - |
| Diarrhoea | 16.4% | 5.7% | - | - |
| Nausea | 15.0% | 11.3% | - | - |
| Dyspnoea | 12.3% | 6.7% | - | - |
| Hypotension | 11.3% | 6.7% | - | - |
| Respiratory failure | 10.5% | 3.0% | - | - |
| Vomiting | 8.9% | 7.2% | - | - |
| Hypokalaemia | 8.9% | 6.2% | - | - |
| Hepatic encephalopathy | 8.5% | 11.3% | - | - |
| Fluid overload | 8.2% | 4.1% | - | - |
Trial register Terlipressin: 2 placebo-controlled trials; Vasopressin: 3. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Terlipressin side effects · Vasopressin side effects
LEGAL STATUS
Approval in each country read
| Country | Terlipressin | Vasopressin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
88 registered trials include both
| NCT07252401 | Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction NOT_YET_RECRUITING · updated 2026-08-27 |
|---|---|
| NCT07746349 | Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery NOT_YET_RECRUITING · updated 2026-08-05 |
| NCT07719933 | Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Prop COMPLETED · updated 2026-07-28 |
| NCT06855758 | Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation ACTIVE_NOT_RECRUITING · updated 2026-07-13 |
| NCT07304466 | Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation RECRUITING · updated 2026-04-29 |
| NCT04961528 | ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial. COMPLETED · updated 2026-04-23 |
| NCT06256432 | Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome ACTIVE_NOT_RECRUITING · updated 2026-04-13 |
| NCT07460908 | Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome COMPLETED · updated 2026-03-10 |
| NCT06161766 | Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease COMPLETED · updated 2025-12-05 |
| NCT05346393 | HRS-AKI Treatment With TIPS in Patients With Cirrhosis RECRUITING · updated 2024-11-18 |
| NCT04460560 | Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) COMPLETED · updated 2024-10-09 |
| 2024-514149-12-00 | Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock. Not stated · updated 2024-08-29 |
| NCT06556472 | Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute UNKNOWN · updated 2024-08-16 |
| NCT05154279 | The Effect of Intramyometrial Injection of Terlipressin Versus Intramyometrial Injection of Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomecto UNKNOWN · updated 2024-06-25 |
| NCT05170230 | The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations UNKNOWN · updated 2024-06-25 |
| NCT05242783 | The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourn COMPLETED · updated 2024-06-25 |
| NCT03130127 | Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis UNKNOWN · updated 2024-02-23 |
| NCT05774067 | Noradrenaline Versus Glypressin for Prevention of Hypotension After Deflation of Tourniquet in Knee Arthroplasty COMPLETED · updated 2023-11-22 |
| NCT06108362 | Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients UNKNOWN · updated 2023-10-31 |
| NCT05875948 | Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome UNKNOWN · updated 2023-10-03 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.